Although the sensitivity of immunohistochemistry in the screening for p53 mutations is only moderate, most cases in daily practice will primarily be assessed by immunohistochemistry, and p53 is an important marker for diagnosing NEC [18]. The gene discussed is TP53; the disease is neuroendocrine carcinoma.